Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

J&J raises FY26 outlook following positive Q2 | PharmaVoice

Pharma Tech

J&J raises FY26 outlook following positive Q2

Jul 15, 2026, 2:14 PM

Read Full Article → J&J raises FY26 outlook following positive Q2

J&J raises FY26 outlook following positive Q2

Translate article text

Choose a language and wait for the translated text.

Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system.